Przeglądanie według Temat "weight loss"

Aktualnie wyświetlane 1 - 2 z 2

Semaglutide – a long – awaited cure for obesity or an elusive treatment?
(Publishing Office of the University of Rzeszow, 2024-12) Oleksak, Izabela; Maliszewska, Karolina; Szawłoga, Tomasz; Welian-Polus, Iwona; Wilanowska, Wiktoria; Babkiewicz-Jahn, Kamila; Matuszewska, Justyna; Szymańska, Adrianna
Introduction and aim. Obesity is a challenging disease that affects various organs and cannot be easily treated. Therefore, the discovery that taking semaglutide results in weight loss caused great excitement amongst patients and medical professionals. The aim of this literature review is to explore the benefits and dangers of semaglutide and its effectiveness in treating obesity. Material and methods. Review of articles published in PubMed since 2017 until first quarter of 2024. Analysis of literature. Obesity is an increasing problem of the world population. There are different approaches in obesity treatment. Semaglutide seems effective in treating diabetes, as well as conditions that emerge from long-lasting obesity. It showed positive influence regarding diabetic neuropathy, cardiovascular risk and more. It is important to remember about possible adverse events. The most prominent are gastrointestinal symptoms, such as nausea, diarrhea, vomiting, and abdominal pain. New reports show complications with simultaneous use of anesthesia or coexisting depression. Larger studies on semaglutiderelated side effects will be published in 2025 and in 2026. Conclusion. Semaglutide is an anti-diabetic drug showing promising effects in treating diabetes and in alleviating conditions caused by obesity. It is worth remembering that its side effects have not yet been fully investigated.
The effect of weight loss on serum ceruloplasmin levels in obese patients
(Publishing Office of the University of Rzeszow, 2023-06) Yigit, Ece; Sayar, Ilknur
Introduction and aim. Serum ceruloplasmin level may be a biomarker associated with obesity and cardiovascular risk. We aimed to evaluate the effect of body weight lost by diet and exercise program on metabolic parameters and serum ceruloplasmin levels in obese patients. Material and methods. A total of 120 obese patients with BMI ≥30 kg/m 2 were enrolled in a 16-week balanced diet program with the goal of losing 10% or more of body weight while maintaining a daily energy deficit of 500-1000 kcal/day. Results. Mean weights of the patients decreased from 93.2±15.1 kg to 83.2±13.1 kg (p<0.001) and mean BMI decreased from 35.8±5.6 kg/m 2 to 31.9±4.9 kg/m 2 (p<0.001). Mean ceruloplasmin decreased from 25.2±4.7 mg/dL to 23.6±4.9 mg/dL (p<0.001), mean total cholesterol from 191.8±37.1 mg/dL to 153.8±28.7 mg/dL (p<0.001), mean LDL from 120.3±31.4 mg/dL to 91.1±27.7 mg/dL (p<0.001) and mean fasting blood glucose from 108.2±35 mg/dL to 103.3±81.1 mg/dL (p<0.001). There was a statistically significant and weak correlation between the change in ceruloplasmin and the change in BMI (p=0.016, R=0.233). There was a statistically significant and weak correlation between ceruloplasmin change and weight change (p=0.010, R=0.251). Conclusion. Obese patients’ serum ceruloplasmin levels were found to decrease with weight loss.